Latest Warner Chilcott Plc (WCRX) Headlines Upt
Post# of 1
Posted On: 03/13/2014 4:15:38 AM
Latest Warner Chilcott Plc (WCRX) Headlines
Uptrend Call Working As Warner Chilcott Stock Rises 69.5% (WCRX)
Comtex SmarTrend(R) - Wed Mar 05, 4:50PM CST
SmarTrend identified an Uptrend for Warner Chilcott (NASDAQ:WCRX) on January 17th, 2013 at $13.53. In approximately 14 months, Warner Chilcott has returned 69.54% as of today's recent price of $22.93.
Cystic Fibrosis Partnering 2009-2014 Research Report
M2 - Thu Feb 27, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4dg6p/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis Partnering 2009-2014" report to their offering. Cystic Fibrosis Partnering 2009-2014 provides understanding and access to the cystic fibrosis partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of cystic fibrosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors cystic fibrosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 50 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of cystic fibrosis partnering trends. In Cystic Fibrosis Partnering 2009-2014, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Key Topics Covered: Executive Summary Introduction Trends in cystic fibrosis partnering Leading cystic fibrosis deals Dealmaking directory Partnering resource center Appendices Table of figures Companies Mentioned Abbott AstraZeneca Baxter International Celgene CSL Daiichi Sankyo Eisai Endo Pharmaceuticals Forest Laboratories Galderma Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Menarini Novartis Novo Nordisk Otsuka Pfizer Purdue Roche Sanofi Takeda Valeant Warner Chilcott Watson For more information visit http://www.researchandmarkets.com/research/b4...c_fibrosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Warner Chilcott Shares Up 69.5% Since SmarTrend's Buy Recommendation (WCRX)
Comtex SmarTrend(R) - Wed Feb 26, 11:01AM CST
SmarTrend identified an Uptrend for Warner Chilcott (NASDAQ:WCRX) on January 17th, 2013 at $13.53. In approximately 14 months, Warner Chilcott has returned 69.54% as of today's recent price of $22.93.
Infectives Partnering Terms and Agreements Report - 2014 Edition
M2 - Tue Feb 25, 9:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/dxxcsm/infectives) has announced the addition of the "Infectives Partnering Terms and Agreements" report to their offering. The Infectives Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter infectives partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors infectives technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in infectives dealmaking Chapter 3 - Leading infectives deals Chapter 4 - Bigpharma infectives deals Chapter 5 - Infectives partnering contracts directory Chapter 6 - Infectives dealmaking by indication Chapter 7 - Partnering resource center Companies Mentioned - Abbott - Actavis - Aspen Pharmacare - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Dainippon Sumitomo - Eisai - Eli Lilly - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Servier - Teva - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/dxxcsm/infectives
2013 Report on Biotechnology Deals and Alliances Includes the Most Up to Date Deal and Company Data
M2 - Mon Feb 17, 6:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/9lxjp7/biotechnology) has announced the addition of the "Biotechnology Deals and Alliances of 2013" report to their offering. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2013's dealmaking and business activities. Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication. Chapter 2 provides a review of the leading deals during 2013. Deals are listed by headline value, signed by Biotechnology and bigbiotech, and most active Biotechnology. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 3 provides a comprehensive listing of the top 50 Biotechnology companies with a brief summary followed by a comprehensive listing of 2013 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 4 provides a comprehensive directory of all partnering deals announced during 2013. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2013. Companies Mentioned: - Abbott - Actavis - Astellas - AstraZeneca - Baxter International - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Daiichi Sankyo - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/9l...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Central Nervous System Deals and Alliances of 2013 Research Report
M2 - Fri Feb 14, 4:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/wwgsqh/central_nervous) has announced the addition of the "Central Nervous System Deals and Alliances of 2013" report to their offering. The Central Nervous System Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2013's dealmaking and business activities. Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication. Chapter 2 provides a review of the leading deals during 2013. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2012 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 4 provides a comprehensive directory of all partnering deals announced during 2013. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2013. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2013. Key Topics Covered: Executive Summary Trends in dealmaking during 2013 Leading deals during 2013 Bigpharma deals during 2013 Partnering deals directory 2013 About Wildwood Ventures Table of figures Companies Mentioned Abbott Baxter International Celgene CSL Daiichi Sankyo Eli Lilly Forest Laboratories Galderma Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Menarini Novartis Otsuka Pfizer Roche Sanofi Takeda Valeant Warner Chilcott Watson and many more... For more information visit http://www.researchandmarkets.com/research/ww...al_nervous About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2013 Report 'Oncology Deals and Alliances' is a Vital Report for those in the Cancer Field
M2 - Thu Feb 13, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/cnkhs3/oncology_deals) has announced the addition of the "Oncology Deals and Alliances of 2013" report to their offering. The Oncology Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013. The initial chapters of this report provide an orientation of 2013's dealmaking and business activities. Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication. Chapter 2 provides a review of the leading deals during 2013. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2013 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 4 provides a comprehensive directory of all partnering deals announced during 2013. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2013. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2013. Companies Mentioned: - Abbott - Actavis - Astellas - AstraZeneca - Baxter International - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/cn...logy_deals About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2013 Study on Animal Health Deals and Alliances Allows You to View all the Partnering and Alliances Deals Announced Worldwide
M2 - Thu Feb 13, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/kf58xl/animal_health) has announced the addition of the "Animal Health Deals and Alliances of 2013" report to their offering. The Animal Health Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013. The initial chapters of this report provide an orientation of 2013's dealmaking and business activities. Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication. Chapter 2 provides a review of the leading deals during 2013. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2013 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 4 provides a comprehensive directory of all partnering deals announced during 2013. The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2013. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2013. Companies Mentioned: - Abbott - Actavis - AstraZeneca - Baxter International - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Novartis - Otsuka - Pfizer - Roche - Sanofi - Servier - Takeda - Teva - Valeant - Warner Chilcott For more information visit http://www.researchandmarkets.com/research/kf...mal_health About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Shares of WCRX Up 69.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 12, 9:12AM CST
SmarTrend identified an Uptrend for Warner Chilcott (NASDAQ:WCRX) on January 17th, 2013 at $13.53. In approximately 13 months, Warner Chilcott has returned 69.54% as of today's recent price of $22.93.
Warner Chilcott Has Returned 69.5% Since SmarTrend Recommendation (WCRX)
Comtex SmarTrend(R) - Tue Feb 04, 4:49PM CST
SmarTrend identified an Uptrend for Warner Chilcott (NASDAQ:WCRX) on January 17th, 2013 at $13.53. In approximately 13 months, Warner Chilcott has returned 69.54% as of today's recent price of $22.93.
Experian Data Quality Launches a New Data Quality Grader App on Salesforce1 AppExchange, the World's Leading Business Apps Marketplace
Marketwire - Tue Feb 04, 8:30AM CST
Experian Data Quality, a part of Experian Marketing Services and a leading provider of contact data management software and services, today announced that it has launched a data quality grader app on Salesforce1 AppExchange, empowering businesses to connect with customers, partners and employees in a whole new way.
International Analysis of the Contraceptives Market - Forecast to 2018
M2 - Wed Jan 29, 4:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/5f6d7p/contraceptives) has announced the addition of the "International Analysis of the Contraceptives Market - Forecast to 2018" report to their offering. The international contraceptive devices market held majority of the market share in 2011 on account of its high usage rates in the European and Asian regions. Contraceptive devices such as copper IUDs, male condoms and cheap subdermal contraceptive implants such as Sino-implants are some of the products responsible for the high market share. In addition, the market share is expected to increase during the forecast period owing to the introduction of cheap and generic contraceptive drugs and the possible introduction of new and technologically advanced products such as Agile Therapeutics' AG200-15, a contraceptive patch currently in pipeline. The new contraceptive patch is currently undergoing phase III clinical trials and is expected to be launched in 2014. The global contraceptives market can be analyzed by segmenting the market into four regions namely: North America, Asia-Pacific, Europe and rest of the world (RoW). The Asia-Pacific contraceptives market is the fastest growing segment due to the rapid economic growth of countries such as India and China. The presence of cheap generic contraceptive pills and devices such as male condoms, copper IUDs and Sino-implants (II) (subdermal contraceptive implant) serves the Asia-Pacific contraceptives market as prominent drivers. Moreover, the presence of a huge population base and high prevalence of sexually transmitted diseases especially in South-East Asian countries have encouraged users to opt for STD-preventing contraceptives such as condoms and has expedited the growth of the Asia-Pacific contraceptives market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Contraceptives Market, by Products Chapter 5 Global Contraceptives Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles Companies Mentioned: - Agile Therapeutics - Bayer HealthCare - BioSante Pharmaceuticals - Church & Dwight - Mayer Laboratories - Merck & Co. - Pantarhei Bioscience - Pfizer - Teva Pharmaceutical Industries - Warner Chilcott Company For more information visit http://www.researchandmarkets.com/research/5f...raceptives
2013 Report on the Global Contraceptives Market - Growth and Forecast to 2018
M2 - Tue Jan 21, 8:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/qsngpt/contraceptives) has announced the addition of the "2013 Report on the Global Contraceptives Market - Growth and Forecast to 2018" report to their offering. This report holds the contraceptives market estimation of the global contraceptives market in terms of value (USD million) for the period 2012 - 2018, considering the base year 2011 as. In addition, current market trends and recent developments are taken into consideration while determining the growth rate of the global contraceptives market. The market is also forecasted in terms of value (USD million) for the period 2012 - 2018 for four major geographic regions namely North America, Asia-Pacific, Europe and the rest of the world. Some of the key market players of the global contraceptives market include Merck, Bayer HealthCare, Church & Dwight, Warner Chilcott Company, Inc., Pfizer, Agile Therapeutics, Biosante Pharmaceuticals, Mayer Laboratories, Pantarhei Bioscience and Teva Pharmaceuticals. Market players are profiled in this report on the basis of parameters such as company overview, business strategies adopted by the companies to ensure sustainability and maximize profits, financial overview and recent developments. The global contraceptive market is categorized into the following segments: - Contraceptives Market by Products - Contraceptive Drugs - Oral Contraceptive Pills - Contraceptive Injectables - Topical Contraceptives - Contraceptive Devices - Male Contraceptive Devices (Male Condoms) - Female Contraceptive Devices - Female Condoms - Diaphragms - Sponges - IUDs - Hormonal IUDs - Copper IUDs - Subdermal Contraceptive Implants - Vaginal Rings Contraceptives Market by Geography: - North America - Europe - Asia-Pacific - Rest of the World (RoW) Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Global Contraceptives Market, by Products 5 Global Contraceptives Market, by Geography 6 Recommendations 7 Company Profiles Companies Mentioned: - Agile Therapeutics Inc. - Bayer HealthCare AG - BioSante Pharmaceuticals Inc. - Church & Dwight, Co. Inc. - Mayer Laboratories, Inc. - Merck & Co. - Pantarhei Bioscience B.V. - Pfizer, Inc. - Teva Pharmaceutical Industries Ltd. - Warner Chilcott Company, Inc. For more information visit http://www.researchandmarkets.com/research/qs...raceptives
Actavis Announces Preliminary Financial Performance for FY 2013
PR Newswire - Tue Jan 14, 7:00AM CST
Actavis plc (NYSE: ACT) today announced that, based on a preliminary review of 2013 results for the fourth quarter ended December 31, 2013, the Company expects non-GAAP earnings per diluted share for the fourth quarter 2013 to be modestly above the high end of its previous forecast.
Global Erectile Dysfunction Clinical Trials Review Report, H2 2013
M2 - Thu Jan 09, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/mpz4sf/erectile) has announced the addition of the "Erectile Dysfunction Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Erectile Dysfunction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Erectile Dysfunction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Bayer AG - Pfizer Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Vivus, Inc. - Johnson & Johnson - SK Chemicals Co., Ltd. - Dong-A Socio Holdings Co Ltd - Warner Chilcott Plc - Vectura Group plc For more information visit http://www.researchandmarkets.com/research/mpz4sf/erectile
Amneal Appoints Rochelle Fuhrmann New Chief Financial Officer
Business Wire - Thu Jan 09, 5:59AM CST
Amneal Pharmaceuticals LLC is pleased to announce that Rochelle Fuhrmann has joined the fast-growing generics manufacturer as Chief Financial Officer.
Uptrend Call Working As Warner Chilcott Stock Rises 69.5% (WCRX)
Comtex SmarTrend(R) - Wed Mar 05, 4:50PM CST
SmarTrend identified an Uptrend for Warner Chilcott (NASDAQ:WCRX) on January 17th, 2013 at $13.53. In approximately 14 months, Warner Chilcott has returned 69.54% as of today's recent price of $22.93.
Cystic Fibrosis Partnering 2009-2014 Research Report
M2 - Thu Feb 27, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4dg6p/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis Partnering 2009-2014" report to their offering. Cystic Fibrosis Partnering 2009-2014 provides understanding and access to the cystic fibrosis partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of cystic fibrosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors cystic fibrosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 50 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of cystic fibrosis partnering trends. In Cystic Fibrosis Partnering 2009-2014, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Key Topics Covered: Executive Summary Introduction Trends in cystic fibrosis partnering Leading cystic fibrosis deals Dealmaking directory Partnering resource center Appendices Table of figures Companies Mentioned Abbott AstraZeneca Baxter International Celgene CSL Daiichi Sankyo Eisai Endo Pharmaceuticals Forest Laboratories Galderma Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Menarini Novartis Novo Nordisk Otsuka Pfizer Purdue Roche Sanofi Takeda Valeant Warner Chilcott Watson For more information visit http://www.researchandmarkets.com/research/b4...c_fibrosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Warner Chilcott Shares Up 69.5% Since SmarTrend's Buy Recommendation (WCRX)
Comtex SmarTrend(R) - Wed Feb 26, 11:01AM CST
SmarTrend identified an Uptrend for Warner Chilcott (NASDAQ:WCRX) on January 17th, 2013 at $13.53. In approximately 14 months, Warner Chilcott has returned 69.54% as of today's recent price of $22.93.
Infectives Partnering Terms and Agreements Report - 2014 Edition
M2 - Tue Feb 25, 9:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/dxxcsm/infectives) has announced the addition of the "Infectives Partnering Terms and Agreements" report to their offering. The Infectives Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter infectives partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors infectives technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in infectives dealmaking Chapter 3 - Leading infectives deals Chapter 4 - Bigpharma infectives deals Chapter 5 - Infectives partnering contracts directory Chapter 6 - Infectives dealmaking by indication Chapter 7 - Partnering resource center Companies Mentioned - Abbott - Actavis - Aspen Pharmacare - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Dainippon Sumitomo - Eisai - Eli Lilly - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Servier - Teva - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/dxxcsm/infectives
2013 Report on Biotechnology Deals and Alliances Includes the Most Up to Date Deal and Company Data
M2 - Mon Feb 17, 6:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/9lxjp7/biotechnology) has announced the addition of the "Biotechnology Deals and Alliances of 2013" report to their offering. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2013's dealmaking and business activities. Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication. Chapter 2 provides a review of the leading deals during 2013. Deals are listed by headline value, signed by Biotechnology and bigbiotech, and most active Biotechnology. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 3 provides a comprehensive listing of the top 50 Biotechnology companies with a brief summary followed by a comprehensive listing of 2013 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 4 provides a comprehensive directory of all partnering deals announced during 2013. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2013. Companies Mentioned: - Abbott - Actavis - Astellas - AstraZeneca - Baxter International - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Daiichi Sankyo - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/9l...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Central Nervous System Deals and Alliances of 2013 Research Report
M2 - Fri Feb 14, 4:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/wwgsqh/central_nervous) has announced the addition of the "Central Nervous System Deals and Alliances of 2013" report to their offering. The Central Nervous System Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2013's dealmaking and business activities. Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication. Chapter 2 provides a review of the leading deals during 2013. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2012 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 4 provides a comprehensive directory of all partnering deals announced during 2013. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2013. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2013. Key Topics Covered: Executive Summary Trends in dealmaking during 2013 Leading deals during 2013 Bigpharma deals during 2013 Partnering deals directory 2013 About Wildwood Ventures Table of figures Companies Mentioned Abbott Baxter International Celgene CSL Daiichi Sankyo Eli Lilly Forest Laboratories Galderma Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Menarini Novartis Otsuka Pfizer Roche Sanofi Takeda Valeant Warner Chilcott Watson and many more... For more information visit http://www.researchandmarkets.com/research/ww...al_nervous About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2013 Report 'Oncology Deals and Alliances' is a Vital Report for those in the Cancer Field
M2 - Thu Feb 13, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/cnkhs3/oncology_deals) has announced the addition of the "Oncology Deals and Alliances of 2013" report to their offering. The Oncology Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013. The initial chapters of this report provide an orientation of 2013's dealmaking and business activities. Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication. Chapter 2 provides a review of the leading deals during 2013. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2013 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 4 provides a comprehensive directory of all partnering deals announced during 2013. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2013. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2013. Companies Mentioned: - Abbott - Actavis - Astellas - AstraZeneca - Baxter International - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/cn...logy_deals About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2013 Study on Animal Health Deals and Alliances Allows You to View all the Partnering and Alliances Deals Announced Worldwide
M2 - Thu Feb 13, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/kf58xl/animal_health) has announced the addition of the "Animal Health Deals and Alliances of 2013" report to their offering. The Animal Health Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013. The initial chapters of this report provide an orientation of 2013's dealmaking and business activities. Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication. Chapter 2 provides a review of the leading deals during 2013. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2013 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 4 provides a comprehensive directory of all partnering deals announced during 2013. The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2013. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2013. Companies Mentioned: - Abbott - Actavis - AstraZeneca - Baxter International - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - GlaxoSmithKline - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Novartis - Otsuka - Pfizer - Roche - Sanofi - Servier - Takeda - Teva - Valeant - Warner Chilcott For more information visit http://www.researchandmarkets.com/research/kf...mal_health About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Shares of WCRX Up 69.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 12, 9:12AM CST
SmarTrend identified an Uptrend for Warner Chilcott (NASDAQ:WCRX) on January 17th, 2013 at $13.53. In approximately 13 months, Warner Chilcott has returned 69.54% as of today's recent price of $22.93.
Warner Chilcott Has Returned 69.5% Since SmarTrend Recommendation (WCRX)
Comtex SmarTrend(R) - Tue Feb 04, 4:49PM CST
SmarTrend identified an Uptrend for Warner Chilcott (NASDAQ:WCRX) on January 17th, 2013 at $13.53. In approximately 13 months, Warner Chilcott has returned 69.54% as of today's recent price of $22.93.
Experian Data Quality Launches a New Data Quality Grader App on Salesforce1 AppExchange, the World's Leading Business Apps Marketplace
Marketwire - Tue Feb 04, 8:30AM CST
Experian Data Quality, a part of Experian Marketing Services and a leading provider of contact data management software and services, today announced that it has launched a data quality grader app on Salesforce1 AppExchange, empowering businesses to connect with customers, partners and employees in a whole new way.
International Analysis of the Contraceptives Market - Forecast to 2018
M2 - Wed Jan 29, 4:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/5f6d7p/contraceptives) has announced the addition of the "International Analysis of the Contraceptives Market - Forecast to 2018" report to their offering. The international contraceptive devices market held majority of the market share in 2011 on account of its high usage rates in the European and Asian regions. Contraceptive devices such as copper IUDs, male condoms and cheap subdermal contraceptive implants such as Sino-implants are some of the products responsible for the high market share. In addition, the market share is expected to increase during the forecast period owing to the introduction of cheap and generic contraceptive drugs and the possible introduction of new and technologically advanced products such as Agile Therapeutics' AG200-15, a contraceptive patch currently in pipeline. The new contraceptive patch is currently undergoing phase III clinical trials and is expected to be launched in 2014. The global contraceptives market can be analyzed by segmenting the market into four regions namely: North America, Asia-Pacific, Europe and rest of the world (RoW). The Asia-Pacific contraceptives market is the fastest growing segment due to the rapid economic growth of countries such as India and China. The presence of cheap generic contraceptive pills and devices such as male condoms, copper IUDs and Sino-implants (II) (subdermal contraceptive implant) serves the Asia-Pacific contraceptives market as prominent drivers. Moreover, the presence of a huge population base and high prevalence of sexually transmitted diseases especially in South-East Asian countries have encouraged users to opt for STD-preventing contraceptives such as condoms and has expedited the growth of the Asia-Pacific contraceptives market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Contraceptives Market, by Products Chapter 5 Global Contraceptives Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles Companies Mentioned: - Agile Therapeutics - Bayer HealthCare - BioSante Pharmaceuticals - Church & Dwight - Mayer Laboratories - Merck & Co. - Pantarhei Bioscience - Pfizer - Teva Pharmaceutical Industries - Warner Chilcott Company For more information visit http://www.researchandmarkets.com/research/5f...raceptives
2013 Report on the Global Contraceptives Market - Growth and Forecast to 2018
M2 - Tue Jan 21, 8:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/qsngpt/contraceptives) has announced the addition of the "2013 Report on the Global Contraceptives Market - Growth and Forecast to 2018" report to their offering. This report holds the contraceptives market estimation of the global contraceptives market in terms of value (USD million) for the period 2012 - 2018, considering the base year 2011 as. In addition, current market trends and recent developments are taken into consideration while determining the growth rate of the global contraceptives market. The market is also forecasted in terms of value (USD million) for the period 2012 - 2018 for four major geographic regions namely North America, Asia-Pacific, Europe and the rest of the world. Some of the key market players of the global contraceptives market include Merck, Bayer HealthCare, Church & Dwight, Warner Chilcott Company, Inc., Pfizer, Agile Therapeutics, Biosante Pharmaceuticals, Mayer Laboratories, Pantarhei Bioscience and Teva Pharmaceuticals. Market players are profiled in this report on the basis of parameters such as company overview, business strategies adopted by the companies to ensure sustainability and maximize profits, financial overview and recent developments. The global contraceptive market is categorized into the following segments: - Contraceptives Market by Products - Contraceptive Drugs - Oral Contraceptive Pills - Contraceptive Injectables - Topical Contraceptives - Contraceptive Devices - Male Contraceptive Devices (Male Condoms) - Female Contraceptive Devices - Female Condoms - Diaphragms - Sponges - IUDs - Hormonal IUDs - Copper IUDs - Subdermal Contraceptive Implants - Vaginal Rings Contraceptives Market by Geography: - North America - Europe - Asia-Pacific - Rest of the World (RoW) Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Global Contraceptives Market, by Products 5 Global Contraceptives Market, by Geography 6 Recommendations 7 Company Profiles Companies Mentioned: - Agile Therapeutics Inc. - Bayer HealthCare AG - BioSante Pharmaceuticals Inc. - Church & Dwight, Co. Inc. - Mayer Laboratories, Inc. - Merck & Co. - Pantarhei Bioscience B.V. - Pfizer, Inc. - Teva Pharmaceutical Industries Ltd. - Warner Chilcott Company, Inc. For more information visit http://www.researchandmarkets.com/research/qs...raceptives
Actavis Announces Preliminary Financial Performance for FY 2013
PR Newswire - Tue Jan 14, 7:00AM CST
Actavis plc (NYSE: ACT) today announced that, based on a preliminary review of 2013 results for the fourth quarter ended December 31, 2013, the Company expects non-GAAP earnings per diluted share for the fourth quarter 2013 to be modestly above the high end of its previous forecast.
Global Erectile Dysfunction Clinical Trials Review Report, H2 2013
M2 - Thu Jan 09, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/mpz4sf/erectile) has announced the addition of the "Erectile Dysfunction Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Erectile Dysfunction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Erectile Dysfunction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Bayer AG - Pfizer Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Vivus, Inc. - Johnson & Johnson - SK Chemicals Co., Ltd. - Dong-A Socio Holdings Co Ltd - Warner Chilcott Plc - Vectura Group plc For more information visit http://www.researchandmarkets.com/research/mpz4sf/erectile
Amneal Appoints Rochelle Fuhrmann New Chief Financial Officer
Business Wire - Thu Jan 09, 5:59AM CST
Amneal Pharmaceuticals LLC is pleased to announce that Rochelle Fuhrmann has joined the fast-growing generics manufacturer as Chief Financial Officer.
(0)
(0)Warner Chilcott Plc (WCRX) Stock Research Links
Scroll down for more posts ▼